HPV-positive murine oral squamous cell carcinoma: development and characterization of a new mouse tumor model for immunological studies.
Human papillomavirus
Immunocompetent mouse model
Oral squamous cell carcinoma
Syngeneic mouse model
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
10 06 2023
10 06 2023
Historique:
received:
16
03
2023
accepted:
22
05
2023
medline:
12
6
2023
pubmed:
10
6
2023
entrez:
9
6
2023
Statut:
epublish
Résumé
Infection with high-risk human papillomavirus (HPV) strains is one of the risk factors for the development of oral squamous cell carcinoma (OSCC). Some patients with HPV-positive OSCC have a better prognosis and respond better to various treatment modalities, including radiotherapy or immunotherapy. However, since HPV can only infect human cells, there are only a few immunocompetent mouse models available that enable immunological studies. Therefore, the aim of our study was to develop a transplantable immunocompetent mouse model of HPV-positive OSCC and characterize it in vitro and in vivo. Two monoclonal HPV-positive OSCC mouse cell lines were established by inducing the expression of HPV-16 oncogenes E6 and E7 in the MOC1 OSCC cell line using retroviral transduction. After confirming stable expression of HPV-16 E6 and E7 with quantitative real-time PCR and immunofluorescence staining, the cell lines were further characterized in vitro using proliferation assay, wound healing assay, clonogenic assay and RNA sequencing. In addition, tumor models were characterized in vivo in C57Bl/6NCrl mice in terms of their histological properties, tumor growth kinetics, and radiosensitivity. Furthermore, immunofluorescence staining of blood vessels, hypoxic areas, proliferating cells and immune cells was performed to characterize the tumor microenvironment of all three tumor models. Characterization of the resulting MOC1-HPV cell lines and tumor models confirmed stable expression of HPV-16 oncogenes and differences in cell morphology, in vitro migration capacity, and tumor microenvironment characteristics. Although the cell lines did not differ in their intrinsic radiosensitivity, one of the HPV-positive tumor models, MOC1-HPV K1, showed a significantly longer growth delay after irradiation with a single dose of 15 Gy compared to parental MOC1 tumors. Consistent with this, MOC1-HPV K1 tumors had a lower percentage of hypoxic tumor area and a higher percentage of proliferating cells. Characteristics of the newly developed HPV-positive OSCC tumor models correlate with the transcriptomic profile of MOC1-HPV cell lines. In conclusion, we developed and characterized a novel immunocompetent mouse model of HPV-positive OSCC that exhibits increased radiosensitivity and enables studies of immune-based treatment approaches in HPV-positive OSCC.
Sections du résumé
BACKGROUND
Infection with high-risk human papillomavirus (HPV) strains is one of the risk factors for the development of oral squamous cell carcinoma (OSCC). Some patients with HPV-positive OSCC have a better prognosis and respond better to various treatment modalities, including radiotherapy or immunotherapy. However, since HPV can only infect human cells, there are only a few immunocompetent mouse models available that enable immunological studies. Therefore, the aim of our study was to develop a transplantable immunocompetent mouse model of HPV-positive OSCC and characterize it in vitro and in vivo.
METHODS
Two monoclonal HPV-positive OSCC mouse cell lines were established by inducing the expression of HPV-16 oncogenes E6 and E7 in the MOC1 OSCC cell line using retroviral transduction. After confirming stable expression of HPV-16 E6 and E7 with quantitative real-time PCR and immunofluorescence staining, the cell lines were further characterized in vitro using proliferation assay, wound healing assay, clonogenic assay and RNA sequencing. In addition, tumor models were characterized in vivo in C57Bl/6NCrl mice in terms of their histological properties, tumor growth kinetics, and radiosensitivity. Furthermore, immunofluorescence staining of blood vessels, hypoxic areas, proliferating cells and immune cells was performed to characterize the tumor microenvironment of all three tumor models.
RESULTS
Characterization of the resulting MOC1-HPV cell lines and tumor models confirmed stable expression of HPV-16 oncogenes and differences in cell morphology, in vitro migration capacity, and tumor microenvironment characteristics. Although the cell lines did not differ in their intrinsic radiosensitivity, one of the HPV-positive tumor models, MOC1-HPV K1, showed a significantly longer growth delay after irradiation with a single dose of 15 Gy compared to parental MOC1 tumors. Consistent with this, MOC1-HPV K1 tumors had a lower percentage of hypoxic tumor area and a higher percentage of proliferating cells. Characteristics of the newly developed HPV-positive OSCC tumor models correlate with the transcriptomic profile of MOC1-HPV cell lines.
CONCLUSIONS
In conclusion, we developed and characterized a novel immunocompetent mouse model of HPV-positive OSCC that exhibits increased radiosensitivity and enables studies of immune-based treatment approaches in HPV-positive OSCC.
Identifiants
pubmed: 37296466
doi: 10.1186/s12967-023-04221-4
pii: 10.1186/s12967-023-04221-4
pmc: PMC10257320
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
376Informations de copyright
© 2023. The Author(s).
Références
Mol Oncol. 2013 Aug;7(4):776-90
pubmed: 23607916
Cancer Res. 2020 Feb 15;80(4):732-746
pubmed: 31848196
BMC Bioinformatics. 2018 Dec 19;19(1):534
pubmed: 30567491
EMBO J. 1989 Dec 1;8(12):3905-10
pubmed: 2555178
Int J Cancer. 2016 Nov 1;139(9):2001-11
pubmed: 27343048
Int J Cancer. 2012 Apr 15;130(8):1726-32
pubmed: 21618514
J Clin Oncol. 2010 Sep 20;28(27):4142-8
pubmed: 20697079
Hum Vaccin Immunother. 2013 Mar;9(3):534-43
pubmed: 23296123
Head Neck Pathol. 2012 Jul;6 Suppl 1:S3-15
pubmed: 22782219
Nature. 2015 Jan 29;517(7536):576-82
pubmed: 25631445
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001 Jun;91(6):622-35
pubmed: 11402272
Cells. 2020 Nov 23;9(11):
pubmed: 33238461
Radiol Oncol. 2022 Apr 07;56(2):173-184
pubmed: 35390246
Oral Dis. 2018 Sep;24(6):948-956
pubmed: 29706018
Arch Otolaryngol Head Neck Surg. 2010 Dec;136(12):1267-73
pubmed: 21173378
Oncogene. 2004 May 13;23(22):3972-9
pubmed: 15077191
Oncogene. 1989 Dec;4(12):1529-32
pubmed: 2556677
J Virol. 1996 Mar;70(3):1873-81
pubmed: 8627712
J Biomed Sci. 2014 May 30;21:52
pubmed: 24885995
Radiother Oncol. 2012 Oct;105(1):14-20
pubmed: 23083497
J Med Imaging Radiat Oncol. 2014 Feb;58(1):89-97
pubmed: 24529061
Nat Rev Immunol. 2013 Apr;13(4):227-42
pubmed: 23470321
Oncoimmunology. 2015 Jan 30;4(1):e965570
pubmed: 25949860
Clin Cancer Res. 2013 Feb 15;19(4):855-64
pubmed: 23251001
Eur J Cancer. 2013 Jul;49(11):2522-30
pubmed: 23571147
J Virol. 1997 May;71(5):3998-4004
pubmed: 9094677
Int J Cancer. 2023 May 1;152(9):1847-1862
pubmed: 36650703
Papillomavirus Res. 2017 Dec;4:1-11
pubmed: 29179862
Exp Cell Res. 2019 Oct 15;383(2):111508
pubmed: 31356815
PLoS Pathog. 2011 Sep;7(9):e1002256
pubmed: 21980285
Cancers (Basel). 2020 Aug 18;12(8):
pubmed: 32824777
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Natl Cancer Inst. 2016 Jan 28;108(6):djv403
pubmed: 26823521
J Natl Cancer Inst. 2003 Dec 3;95(23):1772-83
pubmed: 14652239
Cancer Res. 2012 Jan 1;72(1):365-74
pubmed: 22086849
Clin Cancer Res. 2014 Jun 1;20(11):2873-84
pubmed: 24668645
Carcinogenesis. 2010 Mar;31(3):473-80
pubmed: 19917629
Lancet Oncol. 2009 Apr;10(4):321-2
pubmed: 19350698
Nat Rev Dis Primers. 2020 Nov 26;6(1):92
pubmed: 33243986
Cancer Res. 1996 Oct 15;56(20):4620-4
pubmed: 8840974
Oncoimmunology. 2019 Feb 6;8(4):e1568809
pubmed: 30906661
Virchows Arch. 2014 Sep;465(3):299-312
pubmed: 25027580
Genes Dev. 1995 Oct 1;9(19):2335-49
pubmed: 7557386
Arch Otolaryngol Head Neck Surg. 2009 Nov;135(11):1137-46
pubmed: 19917928
Br J Cancer. 2023 May;128(10):1819-1827
pubmed: 36765175
J Virol. 1995 Oct;69(10):6389-99
pubmed: 7666540
J Natl Cancer Inst. 2000 May 3;92(9):709-20
pubmed: 10793107
Arch Otolaryngol Head Neck Surg. 2007 May;133(5):495-502
pubmed: 17515506
Cancer Res. 1990 Oct 15;50(20):6502-7
pubmed: 2208109
Int J Cancer. 2020 Dec 1;147(11):3236-3249
pubmed: 32478869
Radiother Oncol. 2021 May;158:262-267
pubmed: 33667590
Radiother Oncol. 2012 Jan;102(1):122-9
pubmed: 21996521
Int J Radiat Oncol Biol Phys. 2009 Jun 1;74(2):553-61
pubmed: 19427557
Front Immunol. 2022 Mar 14;13:812822
pubmed: 35359980
J Virol. 1999 Jul;73(7):5887-93
pubmed: 10364340
Oral Oncol. 2022 Sep;132:106012
pubmed: 35820346
Cancer Res. 2014 Apr 1;74(7):2073-81
pubmed: 24525739
Int J Cancer. 2019 Apr 1;144(7):1619-1632
pubmed: 30230542
BMC Cancer. 2020 Apr 15;20(1):316
pubmed: 32293356
Cell. 1990 Dec 21;63(6):1129-36
pubmed: 2175676
Int J Cancer. 2003 Apr 10;104(3):336-44
pubmed: 12569557
Br J Oral Maxillofac Surg. 2007 Mar;45(2):116-22
pubmed: 16781026
Cancer. 2001 Aug 15;92(4):805-13
pubmed: 11550151
Br J Cancer. 2015 Sep 15;113(6):886-93
pubmed: 26313665
Cancer Causes Control. 2007 Nov;18(9):919-29
pubmed: 17647085
Int J Mol Sci. 2020 Aug 20;21(17):
pubmed: 32825343
J Natl Cancer Inst. 2008 Feb 20;100(4):261-9
pubmed: 18270337
Strahlenther Onkol. 2014 Sep;190(9):839-46
pubmed: 24715240
Proc Natl Acad Sci U S A. 2014 Oct 28;111(43):15544-9
pubmed: 25313082
Lancet Oncol. 2020 Sep;21(9):e419-e430
pubmed: 32888471
J Oncol. 2012;2012:571862
pubmed: 22315596
Philos Trans R Soc Lond B Biol Sci. 2019 May 27;374(1773):20180289
pubmed: 30955493
Crit Rev Oncol Hematol. 2020 Jun;150:102966
pubmed: 32371338
Laryngoscope. 2017 Dec;127(12):2777-2783
pubmed: 28561270
Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1654-8
pubmed: 7878034
Int J Exp Pathol. 2020 Feb;101(1-2):45-54
pubmed: 32436348
Head Neck. 2009 Jul;31(7):911-8
pubmed: 19283850
J Clin Oncol. 2006 May 1;24(13):2098-104
pubmed: 16648512
Oral Oncol. 2013 Jun;49(6):560-6
pubmed: 23578372
Virology. 2010 Nov 10;407(1):60-7
pubmed: 20797753
Nat Rev Cancer. 2010 Aug;10(8):550-60
pubmed: 20592731
mBio. 2020 May 12;11(3):
pubmed: 32398315
Onco Targets Ther. 2016 Jan 27;9:545-55
pubmed: 26869799
Proc Natl Acad Sci U S A. 2020 Nov 10;117(45):27811-27819
pubmed: 33109723
Cancer Biol Med. 2021 Mar 27;:
pubmed: 33772505
J Hematol Oncol. 2012 Jun 28;5:34
pubmed: 22742411
Cancer Rep (Hoboken). 2018 Oct;1(3):e1125
pubmed: 32721084
Arch Gynecol Obstet. 2015 Dec;292(6):1345-54
pubmed: 26093522
Cells. 2020 Jul 27;9(8):
pubmed: 32727072
Proc Natl Acad Sci U S A. 2013 Jan 29;110(5):E415-24
pubmed: 23271806
Cell Rep. 2019 Nov 5;29(6):1660-1674.e7
pubmed: 31693903